Cholesterol is ubiquitous in cells; it plays a critical
role in
membrane structure and transport as well as in intracellular trafficking
processes. There are suggestions that cholesterol metabolism is linked
to innate immunity with inhibitors of DHCR7, the last enzyme in the
cholesterol pathway, suggested to have potential as viral therapeutics
nearly a decade ago. In fact, there are a number of highly prescribed
pharmaceuticals that are off-target inhibitors of DHCR7, causing increased
cellular levels of 7-dehydrodesmosterol (7-DHD) and 7-dehydrocholesterol
(7-DHC). We report here dose–response studies of six such inhibitors
on late-stage cholesterol biosynthesis in Neuro2a cells as well as
their effect on infection of vesicular stomatitis virus (VSV). Four
of the test compounds are FDA-approved drugs (cariprazine, trazodone,
metoprolol, and tamoxifen), one (ifenprodil) has been the object of
a recent Phase 2b COVID trial, and one (AY9944) is an experimental
compound that has seen extensive use as a DHCR7 inhibitor. The three
FDA-approved drugs inhibit replication of a GFP-tagged VSV with efficacies
that mirror their effect on DHCR7. Ifenprodil and AY9944 have complex
inhibitory profiles, acting on both DHCR7 and DHCR14, while tamoxifen
does not inhibit DHCR7 and is toxic to Neuro2a at concentrations where
it inhibits the Δ7−Δ8 isomerase of the cholesterol
pathway. VSV itself affects the sterol profile in Neuro2a cells, showing
a dose–response increase of dehydrolathosterol and lathosterol,
the substrates for DHCR7, with a corresponding decrease in desmosterol
and cholesterol. 7-DHD and 7-DHC are orders of magnitude more vulnerable
to free radical chain oxidation than other sterols as well as polyunsaturated
fatty esters, and the effect of these sterols on viral infection is
likely a reflection of this fact of Nature.